MENU
+Compare
CMOPF
Stock ticker: OTC
AS OF
Dec 17 closing price
Price
$66.93
Change
-$2.69 (-3.86%)
Capitalization
827.91M

CMOPF stock forecast, quote, news & analysis

CMOPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for CMOPF with price predictions
Jan 08, 2025

Momentum Indicator for CMOPF turns positive, indicating new upward trend

CMOPF saw its Momentum Indicator move above the 0 level on January 02, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator turned positive. In of the 14 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis
Bearish Trend Analysis

The Aroon Indicator for CMOPF entered a downward trend on December 30, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.701) is normal, around the industry mean (5.632). P/E Ratio (68.493) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.004). Dividend Yield (0.023) settles around the average of (0.164) among similar stocks. CMOPF's P/S Ratio (7.107) is slightly higher than the industry average of (3.643).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CMOPF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMOPF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 86.34B. The market cap for tickers in the group ranges from 72.83K to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 0%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was -7%. ORINY experienced the highest price growth at 12%, while KYKOF experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 13%. For the same stocks of the Industry, the average monthly volume growth was -6% and the average quarterly volume growth was 40%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 26
P/E Growth Rating: 70
Price Growth Rating: 61
SMR Rating: 60
Profit Risk Rating: 77
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
CMOPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
Sir John Rogerson’s Quay
Phone
+353 18170370
Employees
295
Web
https://www.cosmopharma.com